Ventripoint Diagnostics Ltd. announced the appointment of Dr. Alvira Macanovic as President of the Corporation effective January 1, 2023. Dr. George Adams will continue as Executive-Chairman of the Corporation with responsibilities for new applications, investor relations and strategic partnerships. Dr. Macanovic has had increasing responsibilities within the Corporation since her appointment as Manager of Regulatory Affairs & Quality Assurance in 2017.

She has been instrumental in building the current cohesive teams for manufacturing, sales and marketing, development, quality assurance, and regulatory affairs as the Vice-President of Operations, as well as effectively engaging the cardiology community and driving strategic partnerships. She has over 15 years of experience in pharmaceutical and medical device related industries where she has worked with researchers, start-ups, SMEs, and multi-national companies to commercialize medical products. Previously, Dr. Macanovic worked for an organization supported through the Centers of Excellence for Commercialization and Research in various leadership roles, including business development, sales, and commercialization strategy the commercialization of medical imaging technologies.

She obtained a Bachelor of Science in Biochemistry from McGill University and a PhD in Chemistry from Concordia University.